AU2002366353A8 - Antisense modulation of estrogen receptor alpha expression - Google Patents
Antisense modulation of estrogen receptor alpha expressionInfo
- Publication number
- AU2002366353A8 AU2002366353A8 AU2002366353A AU2002366353A AU2002366353A8 AU 2002366353 A8 AU2002366353 A8 AU 2002366353A8 AU 2002366353 A AU2002366353 A AU 2002366353A AU 2002366353 A AU2002366353 A AU 2002366353A AU 2002366353 A8 AU2002366353 A8 AU 2002366353A8
- Authority
- AU
- Australia
- Prior art keywords
- estrogen receptor
- receptor alpha
- alpha expression
- antisense modulation
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010007005 Estrogen Receptor alpha Proteins 0.000 title 1
- 102100038595 Estrogen receptor Human genes 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/027,983 US6617162B2 (en) | 2001-12-18 | 2001-12-18 | Antisense modulation of estrogen receptor alpha expression |
US10/027,983 | 2001-12-18 | ||
PCT/US2002/040083 WO2003052072A2 (en) | 2001-12-18 | 2002-12-13 | Antisense modulation of estrogen receptor alpha expression |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002366353A1 AU2002366353A1 (en) | 2003-06-30 |
AU2002366353A8 true AU2002366353A8 (en) | 2003-06-30 |
Family
ID=21840912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002366353A Abandoned AU2002366353A1 (en) | 2001-12-18 | 2002-12-13 | Antisense modulation of estrogen receptor alpha expression |
Country Status (3)
Country | Link |
---|---|
US (2) | US6617162B2 (en) |
AU (1) | AU2002366353A1 (en) |
WO (1) | WO2003052072A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7846906B2 (en) | 2003-02-28 | 2010-12-07 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
CN100424183C (en) * | 2003-09-17 | 2008-10-08 | 中山大学达安基因股份有限公司 | Method and its kit for early testing SARS virus infection |
US20050239112A1 (en) * | 2004-04-01 | 2005-10-27 | Migenix, Inc. | Methods and processes for attaching compounds to matrices |
US7585968B2 (en) * | 2005-03-28 | 2009-09-08 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to thymus and activation-regulated chemokine (TARC) |
DK1973946T3 (en) | 2006-01-20 | 2015-06-22 | Cell Signaling Technology Inc | TRANSLOCATION AND MUTANT ROSE KINASE IN HUMAN NON-SMALL CELL LUNGCARCINOM |
US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
SI2450437T1 (en) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc. | Gene defects and mutant ALK kinase in human solid tumors |
JP5769968B2 (en) | 2007-10-18 | 2015-08-26 | セル・シグナリング・テクノロジー・インコーポレイテツド | Translocation and mutant ROS kinase in human non-small cell lung cancer |
US8916531B2 (en) * | 2007-11-20 | 2014-12-23 | Isis Pharmaceuticals, Inc. | Modulation of CD40 expression |
EP2274423A2 (en) * | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
IT1392567B1 (en) * | 2008-12-24 | 2012-03-09 | Bioindustry Park Del Canavese S P A | USE OF A PEPTIDE DERIVED FROM ER-ALPHA FOR THE RESTORATION OF SENSITIVITY TO ANTIESTROGENIC COMPOUNDS IN MAMMARY TUMOR CELLS |
US9364477B2 (en) | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
US8841269B2 (en) * | 2010-02-23 | 2014-09-23 | Creighton University | Polynucleotides for use in treating and diagnosing cancers |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
WO2013148260A1 (en) | 2012-03-30 | 2013-10-03 | Washington University | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
EP2838998B1 (en) | 2012-04-18 | 2017-10-11 | Cell Signaling Technology, Inc. | Egfr and ros1 in cancer |
CN102703591B (en) * | 2012-05-30 | 2014-04-23 | 北京艾迪康医学检验所有限公司 | Primer used for performing pyrophosphoric acid detection on PvuII and XbaI polymorphism of intron 1 of estrogen receptor gene alpha |
ES2809199T3 (en) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulation of UBE3A-ATS expression |
TW202246503A (en) * | 2013-07-19 | 2022-12-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
PE20210451A1 (en) | 2015-11-12 | 2021-03-08 | Hoffmann La Roche | OLIGONUCLEOTIDES TO INDUCE PATERNAL EXPRESSION OF UBE3A |
JOP20210261A1 (en) | 2019-03-29 | 2023-01-30 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating ube3a-ats |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5578444A (en) * | 1991-06-27 | 1996-11-26 | Genelabs Technologies, Inc. | Sequence-directed DNA-binding molecules compositions and methods |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US6156513A (en) * | 1995-09-15 | 2000-12-05 | Ramareddy V. Guntaka | Oligmers which inhibit expression of collagen genes |
US6235872B1 (en) | 1998-03-12 | 2001-05-22 | The Burnham Institute | Proapoptotic peptides dependence polypeptides and methods of use |
CA2326823A1 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
AU5316600A (en) | 1999-06-04 | 2000-12-28 | Board Of Regents, The University Of Texas System | Estrogen receptor site-specific ribozymes and uses thereof for estrogen dependent tumors |
IT1313552B1 (en) | 1999-06-29 | 2002-09-09 | European Molecular Biology Lab Embl | ISOFORMS OF THE HUMAN ESTROGEN ALPHA RECEPTOR |
CA2400915A1 (en) | 2000-02-22 | 2001-08-30 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
-
2001
- 2001-12-18 US US10/027,983 patent/US6617162B2/en not_active Expired - Lifetime
-
2002
- 2002-12-13 WO PCT/US2002/040083 patent/WO2003052072A2/en not_active Application Discontinuation
- 2002-12-13 AU AU2002366353A patent/AU2002366353A1/en not_active Abandoned
-
2003
- 2003-05-30 US US10/448,753 patent/US20030211611A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6617162B2 (en) | 2003-09-09 |
US20030211611A1 (en) | 2003-11-13 |
AU2002366353A1 (en) | 2003-06-30 |
WO2003052072A2 (en) | 2003-06-26 |
WO2003052072A3 (en) | 2004-03-04 |
US20030139360A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002366353A8 (en) | Antisense modulation of estrogen receptor alpha expression | |
AU2003283966A8 (en) | Antisense modulation of farnesoid x receptor expression | |
AU2002227435A1 (en) | Antisense modulation of calreticulin expression | |
AU2002332924A1 (en) | Antisense modulation of pka regulatory subunit rii alpha expression | |
HK1160494A1 (en) | Antisense modulation of ptp1b expression ptp1b | |
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU3658101A (en) | Antisense modulation of survivin expression | |
AU2002364125A8 (en) | Antisense modulation of mdm2 expression | |
EP1206478A4 (en) | Antisense modulation of mekk5 expression | |
AU2002366788A8 (en) | Antisense modulation of ship-1 expression | |
AU2002320525A1 (en) | Antisense modulation of glioma-associated oncogene-2 expression | |
AU2002359574A8 (en) | Antisense modulation of g protein-coupled receptor etbr-lp-2 expression | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
AU2003233634A8 (en) | Antisense modulation of glucocorticoid receptor expression | |
AU2002357102A8 (en) | Antisense modulation of cd36l1 expression | |
AU2003257966A8 (en) | Antisense modulation of lar expression | |
EP1434786A4 (en) | Androstane 17-beta-carboxamides as androgen receptor modulators | |
EP1203010A4 (en) | Antisense modulation of fadd expression | |
IL188485A0 (en) | New use of iloperidone | |
AU2002353076A1 (en) | Antisense modulation of estrogen receptor beta expression | |
AU2002347809A1 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
AU2002217853A1 (en) | Antisense modulation of src-1 expression | |
AU2002359352A1 (en) | Antisense modulation of thyroid hormone receptor interactor 6 expression | |
AU2002319635A1 (en) | Antisense modulation of short heterodimer partner-1 expression | |
AU2002346632A8 (en) | Antisense modulation of mhc class ii transactivator expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |